secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001724521-25-000099
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences Q2 2025 rev $160M (incl $143M one-time), net income breakeven; casdatifan Phase 3 trials initiated
--------------------------------------------------------------------------------

- Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).
- Q2 2025 revenue $160M vs $39M YoY, driven by $143M cumulative catch-up from etrumadenant program pause.
- R&D expenses $139M (vs $115M Q2 2024); CMC costs expected elevated through Q3, then decline from Q4.
- PEAK-1 (Phase 3 casdatifan + cabozantinib) and eVOLVE-RCC02 (Phase 1b/3 with AstraZeneca) initiated in ccRCC.
- Quemliclustat granted FDA Orphan Drug Designation for pancreatic cancer; PRISM-1 enrollment completion expected Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/0001724521-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/rcus-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer